大阪大学 · 医学
Uemura教授の研究室は、前立腺がんの治療抵抗性や転移のメカニズムを解明することを目的としており、特にホルモン refractory 前立腺がん（HRPC）におけるステロイド代謝酵素の役割や、がん由来エクソームのプロテオーム解析を通じた新規治療標的の同定を進めています。特に、腫瘍微小環境や体液中を循環するエクソームを標的にしたがんの進行メカニズム解明が、今後の治療戦略の立案に貢献すると期待されています。
Figures are computed from collected data and may differ slightly.
Prostate cancer often relapses during androgen-depletion therapy, even under conditions in which a drastic reduction of circulating androgens is observed. There is some evidence that androgens remain present in the tissues of hormone-refractory prostate cancers (HRPC), and enzymes involved in the androgen and steroid metabolic pathway are likely to be active in HRPC cells. We previously carried out a genome-wide gene expression profile analysis of clinical HRPC cells by means of cDNA microarrays
The phase 3 JAVELIN Renal 101 trial of avelumab + axitinib vs sunitinib in patients with treatment-naive advanced renal cell carcinoma (RCC) demonstrated significantly improved progression-free survival (PFS) and higher objective response rate (ORR) with the combination vs sunitinib. Japanese patients enrolled in the study (N = 67) were randomized to receive avelumab + axitinib (N = 33) or sunitinib (N = 34); 67% vs 59% had PD-L1+ tumors (≥1% of immune cells) and 6%/64%/27% vs 6%/82%/12% had Int
Prostate cancer is the second leading cause of cancer death in men in the United States. Several novel therapeutic agents have been developed for castration-resistant prostate cancer (CRPC), but the prognosis for patients with CRPC remains poor. The identification of novel therapeutic targets for CRPC is an urgent issue. Exosomes are small vesicles secreted by a variety of cells, and exosomes derived from cancer cells have been reported to circulate in the patient's bodily fluids, promoting meta
Open papers in the app to read, cite, and organize with AI.
